Nisa Investment Advisors LLC Grows Stake in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Nisa Investment Advisors LLC grew its holdings in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 973.3% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 4,669 shares of the medical technology company’s stock after acquiring an additional 4,234 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Alphatec were worth $43,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. XTX Topco Ltd bought a new stake in Alphatec in the third quarter valued at $69,000. Net Worth Advisory Group purchased a new position in shares of Alphatec during the third quarter valued at about $76,000. Van ECK Associates Corp raised its stake in Alphatec by 57.0% in the third quarter. Van ECK Associates Corp now owns 19,273 shares of the medical technology company’s stock worth $99,000 after buying an additional 6,998 shares in the last quarter. Tempus Wealth Planning LLC purchased a new stake in Alphatec in the third quarter worth about $107,000. Finally, Atria Investments Inc boosted its position in Alphatec by 8.0% during the 3rd quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company’s stock valued at $109,000 after acquiring an additional 1,460 shares in the last quarter. Institutional investors own 66.35% of the company’s stock.

Insider Buying and Selling

In related news, CEO Patrick Miles sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $12.03, for a total transaction of $601,500.00. Following the completion of the sale, the chief executive officer now owns 6,152,544 shares of the company’s stock, valued at $74,015,104.32. This trade represents a 0.81 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP David Sponsel sold 58,283 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $10.71, for a total transaction of $624,210.93. Following the completion of the transaction, the executive vice president now owns 502,311 shares of the company’s stock, valued at approximately $5,379,750.81. The trade was a 10.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 115,208 shares of company stock worth $1,308,335 in the last quarter. Corporate insiders own 22.80% of the company’s stock.

Alphatec Trading Up 0.3 %

Alphatec stock opened at $11.79 on Friday. Alphatec Holdings, Inc. has a 12 month low of $4.88 and a 12 month high of $17.34. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. The business’s fifty day simple moving average is $10.12 and its two-hundred day simple moving average is $8.12. The company has a market capitalization of $1.67 billion, a price-to-earnings ratio of -9.21 and a beta of 1.41.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on ATEC shares. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research report on Tuesday, January 14th. Barclays increased their price objective on Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Wednesday, January 22nd. Finally, Needham & Company LLC boosted their target price on shares of Alphatec from $13.00 to $16.00 and gave the company a “buy” rating in a report on Monday, January 13th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.56.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.